Apr. 5 at 5:48 PM
$BCYC New leadership across the board — new CFO, CMO, and CSO all announced.
That's either a fresh start or a sign of how badly the old strategy failed, depending on how you read it.
The swing trader's lens on this:
The April 17-22 AACR conference is the obvious near-term event. Five abstracts being presented.
If BT5528 combo data with nivolumab looks clean, the stock could move — it's been beaten down enough that good data has room to run.
The cash position (648M to 2030) is a real floor, though you'd want to know the exact share count from the
$555M raise to figure out how much dilution happened.
The risk is that the company just lost its lead drug, is burning cash on a restructuring, and is pivoting into two areas (PDAC and radiopharma) where they're unproven.
That's a lot of uncertainty baked into one ticker.
For a swing trade around a catalyst like AACR, it could be interesting.
As a longer-term hold through a full pipeline rebuild — that's a much harder story to own.
